PTGX
Price
$46.34
Change
+$1.58 (+3.53%)
Updated
Sep 19, 10:45 AM (EDT)
48 days until earnings call
RCUS
Price
$16.96
Change
+$0.47 (+2.85%)
Updated
Sep 19, 10:47 AM (EDT)
47 days until earnings call
Ad is loading...

PTGX vs RCUS

Header iconPTGX vs RCUS Comparison
Open Charts PTGX vs RCUSBanner chart's image
Protagonist Therapeutics
Price$46.34
Change+$1.58 (+3.53%)
Volume$813
CapitalizationN/A
Arcus Biosciences
Price$16.96
Change+$0.47 (+2.85%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
PTGX vs RCUS Comparison Chart
Loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
PTGX vs. RCUS commentary
Sep 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a Hold and RCUS is a Hold.

COMPARISON
Comparison
Sep 19, 2024
Stock price -- (PTGX: $44.77 vs. RCUS: $16.49)
Brand notoriety: PTGX and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTGX: 84% vs. RCUS: 95%
Market capitalization -- PTGX: $2.65B vs. RCUS: $1.51B
PTGX [@Biotechnology] is valued at $2.65B. RCUS’s [@Biotechnology] market capitalization is $1.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $599.73B to $0. The average market capitalization across the [@Biotechnology] industry is $3.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTGX’s FA Score shows that 2 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • PTGX’s FA Score: 2 green, 3 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, PTGX is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTGX’s TA Score shows that 4 TA indicator(s) are bullish while RCUS’s TA Score has 5 bullish TA indicator(s).

  • PTGX’s TA Score: 4 bullish, 4 bearish.
  • RCUS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than PTGX.

Price Growth

PTGX (@Biotechnology) experienced а -0.04% price change this week, while RCUS (@Biotechnology) price change was -2.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.81%. For the same industry, the average monthly price growth was +7.77%, and the average quarterly price growth was +2.01%.

Reported Earning Dates

PTGX is expected to report earnings on Nov 06, 2024.

RCUS is expected to report earnings on Nov 05, 2024.

Industries' Descriptions

@Biotechnology (+7.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($2.65B) has a higher market cap than RCUS($1.51B). PTGX YTD gains are higher at: 95.246 vs. RCUS (-13.665). PTGX has higher annual earnings (EBITDA): 156M vs. RCUS (-235M). RCUS has more cash in the bank: 969M vs. PTGX (564M). PTGX (11M) and RCUS (11M) have identical debt. PTGX has higher revenues than RCUS: PTGX (319M) vs RCUS (247M).
PTGXRCUSPTGX / RCUS
Capitalization2.65B1.51B175%
EBITDA156M-235M-66%
Gain YTD95.246-13.665-697%
P/E Ratio16.46N/A-
Revenue319M247M129%
Total Cash564M969M58%
Total Debt11M11M100%
FUNDAMENTALS RATINGS
PTGX vs RCUS: Fundamental Ratings
PTGX
RCUS
OUTLOOK RATING
1..100
1514
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
4370
SMR RATING
1..100
2296
PRICE GROWTH RATING
1..100
3654
P/E GROWTH RATING
1..100
2298
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (57) in the Pharmaceuticals Major industry is in the same range as PTGX (67) in the Biotechnology industry. This means that RCUS’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (43) in the Biotechnology industry is in the same range as RCUS (70) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew similarly to RCUS’s over the last 12 months.

PTGX's SMR Rating (22) in the Biotechnology industry is significantly better than the same rating for RCUS (96) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew significantly faster than RCUS’s over the last 12 months.

PTGX's Price Growth Rating (36) in the Biotechnology industry is in the same range as RCUS (54) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew similarly to RCUS’s over the last 12 months.

PTGX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for RCUS (98) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew significantly faster than RCUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTGXRCUS
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
73%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
View a ticker or compare two or three
Ad is loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BIEEX16.34N/A
N/A
BlackRock GA Dynamic Eq Instl
RSERX20.28N/A
N/A
Victory Sophus Emerging Markets R6
GCTCX41.27N/A
N/A
Goldman Sachs US Tax-Managed Eq C
SNOAX33.41N/A
N/A
Easterly Snow Long/Short Opportunity A
FMMMX43.56-0.10
-0.23%
American Funds AMCAP 529-F-2

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with RCKT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
-0.31%
RCKT - PTGX
46%
Loosely correlated
-4.40%
NTLA - PTGX
45%
Loosely correlated
-0.13%
VIR - PTGX
44%
Loosely correlated
-1.51%
RCUS - PTGX
43%
Loosely correlated
-1.43%
BEAM - PTGX
41%
Loosely correlated
-0.27%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with NTLA. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-1.43%
NTLA - RCUS
54%
Loosely correlated
-0.13%
PRME - RCUS
51%
Loosely correlated
-0.50%
SNDX - RCUS
50%
Loosely correlated
-0.33%
DNLI - RCUS
50%
Loosely correlated
+0.26%
OCUL - RCUS
49%
Loosely correlated
+3.42%
More